Modular Medical, Inc., a development stage medical device company, focuses on the design, development, and commercialization of insulin pumps using technology to enhance pump adoption in the diabetes marketplace. The company is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: https://www.modular-medical.com
10-Q/A - Modular Medical, Inc. (0001074871) (Filer)
8-K - Modular Medical, Inc. (0001074871) (Filer)
424B5 - Modular Medical, Inc. (0001074871) (Filer)
424B5 - Modular Medical, Inc. (0001074871) (Filer)
10-Q - Modular Medical, Inc. (0001074871) (Filer)
8-K - Modular Medical, Inc. (0001074871) (Filer)
8-K - Modular Medical, Inc. (0001074871) (Filer)
10-Q - Modular Medical, Inc. (0001074871) (Filer)
424B5 - Modular Medical, Inc. (0001074871) (Filer)
10-K - Modular Medical, Inc. (0001074871) (Filer)
-Modular Medical will collaborate with Nudge BG to bring to market an adaptive full closed loop Automated Insulin Delivery system that does not require mealtime announcements-Effort will be led be Nudge BG founder and noted AID expert, Lane Desborough SAN DIEGO, CALIFORNIA / ACCESSWIRE / December 19, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to meet the needs of "almost-pumpers" with its user-friendly and affordable design, announced a licensing and partnership agreement with Nudge BG."We are very excited to partner with Modular Medical to bring the next g
SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced it will hold a conference call and webcast on Thursday, December 5, 2024, at 10:00 a.m. Eastern Time to provide a business update.Conference Call and Webcast InformationDate: December 5, 2024Time: 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time)Conference Call Number: 1-888-506-0062International Call Number: +1-973-528-0011Passcode: 494842Webcast: CLICK HEREFor those unable to
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has priced an underwritten public offering (the "offering") of 5,450,573 shares of its common stock. The offering was led by existing institutional investors, including Manchester Explorer, L.P., which is the largest shareholder of the Company and is managed by Jeb Besser, Modular Medical's Chief Executive Officer. The shares of common stock are being sold at a price t
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it has commenced an underwritten public offering (the "offering") of shares of its common stock (or pre-funded warrants to purchase shares of its common stock in lieu thereof). Modular Medical also has granted the underwriter a 30-day option to purchase up to an additional 15% of the aggregate number of shares of its common stock (or pre-funded warrants) sold in the offering. The offering
SAN DIEGO, CA / ACCESSWIRE / November 11, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced that it is a Gold sponsor of the upcoming, first annual Achieving Diabetes Equity in Practice Today (ADEPT) Conference taking place at the Chicago Marriott Downtown on November 12 and 13,2024. The ADEPT Conference, which is the result of a collaborative effort between the American Diabetes Association and the T1D Exchange, will bring together key stakeholders focused on achiev
Meet with Modular Medical CEO, Jeb BesserObesity is linked to 30% to 53% of new diabetes cases in the U.S. every year, per research in the Journal of the American Heart AssociationAbout half of all patients prescribed a GLP-1 drug for weight loss discontinued after the first 12 weeks, with approximately 30% discontinuing in the first four weeksDiscover Modular Medical's Recently Announced Results from a Successful GLP-1 Proof of Concept Study SAN DIEGO, CA / ACCESSWIRE / November 8, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insu
-Study showed more potent weight loss and blood glucose control with the addition of a mealtime bolus of a rapid acting GLP-1 to basal delivery- Observed weight loss was 17% at 28 days, a 25% improvement over GLP-1 delivered as basal alone-Findings suggest that pump delivery may be a viable approach to achieve GLP-1 weight and blood glucose benefits that are comparable with current treatment standards, either as initial treatment or for maintenance, while bringing personalized dosing flexibility SAN DIEGO, CA / ACCESSWIRE / November 7, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump
Also appearing on the show are, Sustainable Green Team (OTCQX:SGTM), Andie Monet with David Fagen, and SEKUR (OTCQX:SWISF)NEW YORK, NY / ACCESSWIRE / October 28, 2024 / New to The Street on Fox Business will air an exclusive lineup of sponsored programming tonight, starting at 11 PM PT. The show will feature in-depth interviews and insights from leading companies across multiple industries, showcasing groundbreaking innovations and strategic business developments. Featured Lineup:Modular Medical, Inc. (NASDAQ:MODD)CEO Jebb Besser will share the company's innovative approach to simplifying diabetes care through cutting-edge medical devices, aiming to improve patient outcomes and revolutioniz
SAN DIEGO, CA / ACCESSWIRE / September 30, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user-friendly and affordable design, will participate in a webcasted presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2024 Investor Conference, taking place virtually on October 1, 2024.Company WebcastThe Company's webcasted presentation will take place at 2:00 p.m. Eastern Time on Tuesday, October 1. The webcast can be accessed by visiting the conference home page at https://lythampartn
Allowed claims cover major features of pumping mechanism in FDA-cleared MODD1 productSAN DIEGO, CA / ACCESSWIRE / September 18, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" thanks to its user-friendly and affordable design, announced the issuance of U.S. Divisional Patent Application No. 17/968,599."The issuance of this patent and the associated claims represent a major step in our efforts to protect the intellectual property in the MODD1 pump platform," stated Jeb Besser, CEO of Modular Medical. "Some of the key features
SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13G - Modular Medical, Inc. (0001074871) (Subject)
SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13G/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13G/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13G - Modular Medical, Inc. (0001074871) (Subject)
SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)
SC 13D/A - Modular Medical, Inc. (0001074871) (Subject)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4/A - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
SAN DIEGO, CA / ACCESSWIRE / June 3, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced that it is set to join the Russell Microcap Index at the conclusion of the 2024 Russell indexes annual reconstitution, effective when the U.S. market opens on July 1, 2024.Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalizatio
SAN DIEGO, CA / ACCESSWIRE / July 6, 2023 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), a development stage insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, today announced the appointment of medical device industry leader Duane DeSisto to its board of directors. Mr. DeSisto was previously President, CEO and Director of Insulet Corporation, developers of the groundbreaking OmniPod Insulin Management System, before retiring in 2014."Duane brings more than 25 years of experience in the medical device industry and is a visionary business leader credited with the launch and transformatio
Schmid brings 40 years of experience in medical devices for drug delivery and diabetes management and a background in high-volume manufacturingSAN DIEGO, CA / ACCESSWIRE / July 26, 2022 / Modular Medical, Inc. (the "Company" or "Modular Medical")(NASDAQ:MODD) today announced that it has appointed industry veteran Kevin Schmid as its Chief Operating Officer. Mr. Schmid brings extensive operations and business development leadership experience in diabetes and drug delivery. As Vice President of Operations and Business Development at Insulet Corporation, he was instrumental in the development, manufacturing, and commercialization of wearable smart drug delivery pumps such as the Omnipod Diabete
Lynn Vos to remain on board of directors Besser brings 25 years of experience in life sciences, technology, capital markets Company reaffirms timeline for 510(k) submission of MODD1 insulin pump to FDASAN DIEGO, CA / ACCESSWIRE / February 24, 2022 / Modular Medical, Inc. (the "Company" or "Modular Medical")(NASDAQ:MODD) today announced that its board of directors has appointed James "Jeb" Besser as Chief Executive Officer. Besser, a company development and capital markets veteran, has served 23 years as managing member of Manchester Management LLC, the Company's largest outside shareholder and development partner since its inception. Lynn Vos, the Company's CEO since August of 2021, will rem
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
4/A - Modular Medical, Inc. (0001074871) (Issuer)
4 - Modular Medical, Inc. (0001074871) (Issuer)
SAN DIEGO, CA / ACCESSWIRE / December 3, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery technology company with the first FDA-cleared patch pump designed specifically to target all adult "almost-pumpers" with its user-friendly and affordable design, today announced it will hold a conference call and webcast on Thursday, December 5, 2024, at 10:00 a.m. Eastern Time to provide a business update.Conference Call and Webcast InformationDate: December 5, 2024Time: 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time)Conference Call Number: 1-888-506-0062International Call Number: +1-973-528-0011Passcode: 494842Webcast: CLICK HEREFor those unable to
SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it will hold a conference call and webcast tomorrow, Thursday, September 5, 2024, at 8:30 a.m. Eastern Time to discuss the U. S. Food and Drug Administration ("FDA") clearance of its MODD1 pump, as well as next steps and milestones.Conference Call and Webcast InformationDate: September 5, 2024Time: 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time)Conference Call Number: 1-88
MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetesDesigned to be simpler and more affordable to expand access to diabetes technology for previously underserved communitiesCommercial availability expected in early 2025 SAN DIEGO, CA / ACCESSWIRE / September 4, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an insulin delivery system technology company preparing to launch a market expansion product with a more accessible, easier to prescribe, and easier to pay for and live with technology, today announced it has received U. S. Food and Drug Administration ("FDA") clearance to market and sell its MODD1 pump in the United States. With its comme
SAN DIEGO, CA / ACCESSWIRE / January 19, 2024 / Modular Medical, Inc. (NASDAQ:MODD) ("Modular Medical" or the "Company"), a development-stage, insulin delivery technology company seeking to launch the next generation of user-friendly and affordable insulin pump technology, today announced the premarket submission of its MODD1 next-generation insulin pump to the FDA for 510(k) clearance."This is an exciting milestone for the Company, as we seek to change the diabetes market. Almost 30 years after the introduction of the first insulin pump, more than three quarters of those who could benefit from wearing a pump do not wear one. It is our belief that our simplified design will encourage many "a